Format

Send to

Choose Destination
J Environ Public Health. 2012;2012:835059. doi: 10.1155/2012/835059. Epub 2011 Dec 29.

A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis.

Author information

1
Environmental Medicine, Santa Barbara, CA 93105, USA. janettehopemd@yahoo.com

Abstract

Ochratoxin A (OTA) exposure via ingestion and inhalation has been described in the literature to cause kidney disease in both animals and humans. This paper reviews Ochratoxin A and its relationship to human health and kidney disease with a focus on a possible association with focal segmental glomerulosclerosis (FSGS) in humans. Prevention and treatment strategies for OTA-induced illness are also discussed, including cholestyramine, a bile-acid-binding resin used as a sequestrant to reduce the enterohepatic recirculation of OTA.

PMID:
22253638
PMCID:
PMC3255309
DOI:
10.1155/2012/835059
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center